Navigation Links
Thomson Reuters Publishes Three Pharma Matters Reports Covering the Third Quarter of 2008
Date:1/21/2009

Quarterly Reports Use Market Intelligence and Competitive Analysis from Thomson Reuters to Highlight Developments in the Global Pharmaceutical Industry

PHILADELPHIA and LONDON, Jan. 21 /PRNewswire/ -- Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, has announced the availability of three Pharma Matters reports covering the time period July - September 2008. The quarterly Pharma Matters series covers all aspects of the pharmaceutical pipeline, leveraging strategic intelligence and competitive analysis from Thomson Pharma(R), Newport Horizon Premium(TM) and the Thomson Messaging Mapping System(SM).

The Ones to Watch - A Thomson Reuters quarterly review of the latest phase changes in the pharmaceutical pipeline, this report is based on strategic data and analysis from Thomson Pharma, the world's leading pharmaceutical competitive intelligence solution. In the report covering Q3 2008, the top five most promising drugs launched or receiving approval were:

    DRUG          DISEASE                     COMPANY

    Zeftera(TM)   Complicated skin and soft   Basilea Pharmaceutica
                  tissue infections

    Firazyr(R)    Hereditary angioedema       Jerini

    Bridion(R)    Reversal of muscle          Schering-Plough
                  relaxants

    Cleviprex(TM) Perioperative               The Medicines Company
                  hypertension

    Xarelto(R)    Venous thromboembolic       Bayer/Ortho-McNeil
                  events                      Pharmaceutical

More analysis, as well as information on drugs entering clinical Phases I, II and III are available in the full report: http://thomsonreuters.com/content/PDF/scientific/pharma/2008totw_q3.pdf.

Movers and Shakers - This report covers the US generics industry using data and analysis from Newport Horizon Premium, the critical product targeting the global business development system. Analysis from the Q3 2008 report includes:

  • The pharmaceutical marketplace continued to demonstrate volatility, and the pace of patent challenges showed no sign of slackening in the third quarter of 2008.
  • During the third quarter of 2008, final approvals were issued on only 77 'A'-rated ANDAs, plummeting down from 142 the quarter before. First-time approvals of generic products by the FDA also dropped from 11 to 8 this quarter.
  • Seven new products (three combination products and four single active ingredient products) were subjected to paragraph IV challenges for the first time in Q3 2008, identical to the previous quarter.
  • Indian groups were in first place in terms of ANDA approvals during Q3 2008. Twelve India-based corporations received a total of 17 final ANDA approvals.
  • In the same time period, 11 US-based companies received a total of 15 approvals, putting the U.S. in second place for this quarter.
  • Mylan of the U.S. and Boehringer Ingelheim of Germany received the most final ANDA approvals (seven each).

To learn more about companies making their mark on the U.S. generics market, click here to read the full report: http://thomsonreuters.com/content/PDF/scientific/pharma/2008ms_q3.pdf

Who is Making the Biggest Splash? - A Thomson Reuters expert review of the organizations that are helping to shape professional opinions on drugs and therapies, using the unique insights of the Thomson Message Mapping System. In this quarterly review of the scientific literature on drugs and therapies, Thomson Reuters assesses the quantity and quality of the materials published by pharmaceutical companies, research institutions and other non-commercial bodies. The top five of the 15 listed organizations that have made the biggest impact as the leading sources of information on medical research from July - September 2008 are:

  1. Novartis
  2. Bristol-Meyers Squibb
  3. Eli Lilly
  4. Pfizer
  5. AstraZeneca

To see the complete list, as well as analysis and methodology, click here to read the full report: http://thomsonreuters.com/content/PDF/scientific/pharma/2008wmtbs_q3.pdf

To sign up for the Thomson Reuters Pharma Matters series of publications visit: http://scientific.thomsonreuters.com/forms/matters/

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Thomson Scientific Predicts Nobel Laureates
2. Thomson Scientific Announces BONDplus for Biological Researchers
3. Hospitals Improve Survival Rates While Treating Sicker Patients Thomson Healthcare Study Shows
4. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
5. Thomson Healthcare Endorsed as Preferred Vendor of Information Products and Services for Virginia Hospitals
6. Thomson Acquires Prous Science
7. Common Early-Warning Symptoms of Ovarian Cancer Identified in CDC/Thomson Healthcare Study
8. Thomson Scientific Ranks Australian Universities and Research Institutes
9. Thomson Scientific Launches Confessions ... of a User Campaign Asking Are You the New Face of Research?
10. Contract Renewal Extends Thomson Healthcares Long-Standing Relationship with University Hospitals
11. Thomson Healthcare Launches Application That Assesses Physician Performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... ... While the practice and profession of Aging Life Care is not new, there ... and resources. Aging Life Care plays an important role as these professionals are prepared ... Care is a holistic, client-centered approach to caring for older adults or others facing ...
(Date:5/5/2016)... ... May 05, 2016 , ... The ... electronic cigarettes, requiring e-cigarette manufacturers to submit their products through an arduous federal ... all vaping products that entered the market since February 15, 2007. That would ...
(Date:5/5/2016)... ... ... This weekend, from Friday, May 6 - Sunday, May 8, fifteen elite athletes from ... Semper Fi Mountain Bike Camp, hosted in conjunction with WTB and Cannondale ... Jason Moeschler, who’ll share pro tips with the injured veterans as they rip down some ...
(Date:5/5/2016)... ... May 05, 2016 , ... LELO has discovered many ... LELO fans reach out via email, social media and on the Volonté blog seeking ... the way I masturbate ‘normal’ or ‘correct’?” , While some methods are more common ...
(Date:5/5/2016)... ... May 05, 2016 , ... An ... all U.S. states and certain Canadian provinces is now available from the International ... Institute (WCRI). , The report, Workers’ Compensation Laws as of January ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Multiple Myeloma Market ... to their offering.       (Logo: ... Myeloma Market and Competitive Landscape Highlights 2016, ... products, Multiple Myeloma epidemiology, Multiple Myeloma market ...
(Date:5/3/2016)... India , May 4, 2016 ... spreads across 154 pages, profiling 09 key companies ... is a professional and in-depth study on the ... a basic overview of the industry including definitions, ... Needles market analysis is provided for the international ...
(Date:5/3/2016)... , May 3, 2016 ACME ... Whelan and Delaware County Councilman ... Nasal Spray in all ACME pharmacies across ... for Disease Control and Prevention (CDC), naloxone has saved 26,463 lives ... officers in Delaware County were authorized to ...
Breaking Medicine Technology: